Connection
David Simpson to Pyridazines
This is a "connection" page, showing publications David Simpson has written about Pyridazines.
|
|
Connection Strength |
|
 |
|
 |
|
0.232 |
|
|
|
-
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21.
Score: 0.129
-
Nguyen A, Rossi S, Croteau D, Best BM, Clifford D, Collier AC, Gelman B, Marra C, McArthur J, McCutchan JA, Morgello S, Simpson D, Ellis RJ, Grant I, Capparelli E, Letendre S. Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 May; 68(5):1161-8.
Score: 0.103
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|